We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.15B
1-Year Est. Return
43.46%
This Fund
S&P 500
This Quarter
Est. Return
+4.78%
1 Year Est. Return
+43.46%
3 Year Est. Return
+131.91%
5 Year Est. Return
+229.29%
10 Year Est. Return
+757.55%
AUM
$232M
AUM Growth
-$7.38M
(-3.1%)
Cap. Flow
-$16.7M
Cap. Flow
% of AUM
-7.19%
Top 10 Holdings %
Top 10 Hldgs %
29.39%
Holding
116
New
2
Increased
6
Reduced
34
Closed
9
Avg Time Held
7.6
quarters
Top 10 Avg Time Held
3.9
quarters
Top 20 Avg Time Held
4.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tvardi Therapeutics
TVRD
|
+$3.76M |
| 2 |
Rocket Pharmaceuticals
RCKT
|
+$523K |
| 3 |
PVH
PVH
|
+$327K |
| 4 |
Comcast
CMCSA
|
+$58.7K |
| 5 |
Netflix
NFLX
|
+$11.4K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGTC
Applied Genetic Technologies Corporation
AGTC
|
+$4.54M |
| 2 |
Qualcomm
QCOM
|
+$2.2M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$1.71M |
| 4 |
KKR & Co
KKR
|
+$1.63M |
| 5 |
MacroGenics
MGNX
|
+$1.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.01% |
| 2 | Communication Services | 22.71% |
| 3 | Energy | 13.38% |
| 4 | Industrials | 12.54% |
| 5 | Technology | 5.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Apple
AAPL
$4.98T
| $8.41M | 3.63% |
319,796
-3,800
| -1% | -$109K |
2013 Q2
10 quarters
|
|
2
AT&T
T
$157B
| $7.65M | 3.3% |
294,444
-3,006
| -1% | -$76.3K |
2013 Q2
10 quarters
|
|
|
3
Comcast
CMCSA
$74.1B
| $7.64M | 3.3% |
270,718
+1,950
| +0.7% | +$58.7K |
2013 Q2
10 quarters
|
|
4
GE Aerospace
GE
$319B
| $7.18M | 3.1% |
48,107
-251
| -0.5% | -$35.6K |
2013 Q2
10 quarters
|
|
5
McKesson
MCK
$112B
| $6.68M | 2.88% |
33,874
| – | – |
2013 Q2
10 quarters
|
|
6
Thermo Fisher Scientific
TMO
$245B
| $6.52M | 2.81% |
45,935
-200
| -0.4% | -$26.7K |
2015 Q2
2 quarters
|
|
7
Alphabet (Google) Class A
GOOGL
$4.33T
| $6.25M | 2.7% |
160,560
-2,800
| -2% | -$104K |
2015 Q3
1 quarter
|
|
|
TRIL
8
DELISTED
Trillium Therapeutics Inc.
TRIL
| $6M | 2.59% |
476,069
-2,500
| -0.5% | -$34.8K |
2015 Q1
3 quarters
|
|
9
Pfizer
PFE
$162B
| $5.91M | 2.55% |
192,818
-84
| -0% | -$2.64K |
2013 Q2
10 quarters
|
|
10
Enterprise Products Partners
EPD
$77.8B
| $5.84M | 2.52% |
228,279
| – | – |
2013 Q2
10 quarters
|
|
11
Danaher
DHR
$157B
| $5.34M | 2.31% |
85,537
| – | – |
2013 Q2
10 quarters
|
|
12
Blackstone
BX
$82.6B
| $5.33M | 2.3% |
182,410
-4,740
| -3% | -$151K |
2013 Q2
10 quarters
|
|
13
LyondellBasell Industries
LYB
$19.4B
| $5.29M | 2.29% |
60,915
| – | – |
2013 Q2
10 quarters
|
|
14
Meta Platforms (Facebook)
META
$1.94T
| $5.28M | 2.28% |
50,423
-550
| -1% | -$56.5K |
2015 Q2
2 quarters
|
|
15
UnitedHealth
UNH
$339B
| $5.17M | 2.23% |
43,933
-450
| -1% | -$52.6K |
2014 Q3
5 quarters
|
|
16
Union Pacific
UNP
$168B
| $4.85M | 2.09% |
62,045
| – | – |
2013 Q2
10 quarters
|
|
17
Liberty Global Class C
LBTYK
$2.87B
| $4.63M | 2% |
130,729
-1,152
| -0.9% | -$41.5K |
2013 Q2
10 quarters
|
|
18
3M
MMM
$83.9B
| $4.26M | 1.84% |
33,787
-48
| -0.1% | -$6.17K |
2013 Q2
10 quarters
|
|
|
19
Tvardi Therapeutics
TVRD
$13.9M
| $4.16M | 1.8% |
+6,857
| New | +$3.76M |
2015 Q4
0 quarters
|
|
20
DELISTED
Paramount Global Class B
PARA
| $3.98M | 1.72% |
84,355
-21,735
| -20% | -$1.02M |
2013 Q2
10 quarters
|
|
|
21
Rocket Pharmaceuticals
RCKT
$252M
| $3.86M | 1.67% |
85,250
+12,000
| +16% | +$523K |
2015 Q3
1 quarter
|
|
22
Lockheed Martin
LMT
$116B
| $3.86M | 1.67% |
17,775
-4
| -0% | -$868 |
2013 Q2
10 quarters
|
|
23
Canadian National Railway
CNI
$71.8B
| $3.75M | 1.62% |
67,090
-23
| -0% | -$1.34K |
2013 Q2
10 quarters
|
|
|
NTI
24
DELISTED
NORTHERN TIER ENERGY LP CLASS A
NTI
| $3.69M | 1.59% |
142,675
-1,500
| -1% | -$38.8K |
2014 Q2
6 quarters
|
|
|
TFCFA
25
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
| $3.6M | 1.55% |
132,636
-19,825
| -13% | -$575K |
2013 Q3
9 quarters
|
|
Similar funds
WB
AIC
CFP
HT
AA
CIG
CIS
FWM
Private Capital Advisors's Q4 2015 Portfolio in Review
As of Q4 2015, Private Capital Advisors held 116 positions worth $232M, down 3.1% from $239M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Private Capital Advisors withdrew a net $16.7M in Q4 2015, closing 9 positions and reducing 34 holdings. Its most notable exit was MacroGenics, an estimated $1.32M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 29% a quarter earlier, followed by Communication Services and Energy.
Against the trend, Private Capital Advisors opened a new position in Tvardi Therapeutics worth $4.16M.
- Private Capital Advisors's largest Q4 2015 buy was Tvardi Therapeutics: 6,857 shares worth $4.16M.
- Private Capital Advisors added most to Rocket Pharmaceuticals in Q4 2015, an estimated $523K increase.
- Private Capital Advisors's biggest Q4 2015 reduction was Applied Genetic Technologies Corporation, cutting an estimated $4.54M.
- Private Capital Advisors fully exited MacroGenics in Q4 2015, selling an estimated $1.32M.
- Private Capital Advisors's ten largest holdings make up 29% of its $232M portfolio in Q4 2015.
- Private Capital Advisors opened 2 new positions and closed 9 in Q4 2015.
- Private Capital Advisors's portfolio value fell 3.1% quarter-over-quarter to $232M.
Based on Private Capital Advisors's 13F filing for Q4 2015, filed 22 Jan 2016.